CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.33B, above the global median of $1.15B
- FinancialsAltman Z-Score 5.17: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.71%Above 5Y avg (0.86%)
Annual Rate
CNY 0.34Paid annual
Payout Ratio
30.2%Sustainable
Payback Period
58.7 yr
Last Ex-Dividend
Jun 15, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
8.94BCNY1.33B · vs all stocks (USD)
Trailing P/E
22.92xvs Biotechnology peers
Revenue (TTM)
1.68BCNY250.54M · vs all stocks (USD)
Profit Margin
23.37%vs Biotechnology peers
Beta
-0.3570xvs all stocks
52-Week Change
-17.06%vs all stocks
Market Capitalization
8.94BCNY1.33B · vs all stocks (USD)
Enterprise Value
8.12BCNY1.21B · vs all stocks (USD)
Trailing P/E
22.92xvs Biotechnology peers
Forward P/E
17.32xvs Biotechnology peers
Price to Sales (TTM)
5.30xvs Biotechnology peers
Price to Book (MRQ)
3.26xvs Biotechnology peers
Enterprise to Revenue
4.82xvs Biotechnology peers
Enterprise to EBITDA
13.30xvs Biotechnology peers
Gross Margin
53.39%vs Biotechnology peers
Profit Margin
23.37%vs Biotechnology peers
Operating Margin
23.55%vs Biotechnology peers
Return on Assets (TTM)
7.40%vs Biotechnology peers
Return on Equity (TTM)
15.26%vs Biotechnology peers
Revenue (TTM)
1.68BCNY250.54M · vs all stocks (USD)
Revenue per Share (TTM)
4.20CNYUpdated Aug 21, 2026Quarterly Revenue Growth
-3.20%vs Biotechnology peers
Gross Profit (TTM)
963.86MCNY143.34M · vs all stocks (USD)
EBITDA (TTM)
503.85MCNY74.93M · vs all stocks (USD)
Net Income (TTM)
393.72MCNY58.55M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-46.50%vs Biotechnology peers
Operating Cash Flow (TTM)
484.02MCNY71.98M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
57.45MCNY8.54M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.3400CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
1.71%vs all stocks
5-Year Average Dividend Yield
0.86%vs all stocks
Payout Ratio
30.21%vs Biotechnology peers
Revenue
1.70BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
684.64MCNYFY2025 · Dec 31, 2025Gross Profit
1.01BCNYFY2025 · Dec 31, 2025Operating Income
559.38MCNY83.18M · vs all stocks (USD)
Pre-tax Income
518.30MCNYFY2025 · Dec 31, 2025Income Tax Expense
69.09MCNYFY2025 · Dec 31, 2025Net Income
449.21MCNYFY2025 · Dec 31, 2025EBIT
553.01MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
692.27MCNYFY2025 · Dec 31, 2025Research & Development
153.39MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
150.13MCNYFY2025 · Dec 31, 2025Other Operating Expenses
15.77MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
13.35MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
34.71MCNYFY2025 · Dec 31, 2025EPS (Basic)
1.12CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.10CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
401.08MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
401.08MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
449.21MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
240.67MCNYFY2025 · Dec 31, 2025Free Cash Flow
-108.37MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
762.37MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
449.21MCNYFY2025 · Dec 31, 2025Other Non-cash Items
40.68MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-125.57MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-123.66MCNYFY2025 · Dec 31, 2025Capital Expenditures
-349.03MCNYFY2025 · Dec 31, 2025Purchase of Investments
-959.60MCNYFY2025 · Dec 31, 2025Sale of Investments
1.07BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-242.19MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
66.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-60.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-124.12MCNYFY2025 · Dec 31, 2025Other Financing Charges
-63.30MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-181.42MCNYFY2025 · Dec 31, 2025Shares Outstanding
406.18MSharesUpdated Aug 21, 2026Float Shares
91.33MSharesUpdated Aug 21, 2026% Held by Insiders
79.08%vs all stocks
% Held by Institutions
3.14%vs all stocks
Total Cash (MRQ)
917.17MCNY136.39M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.27CNYUpdated Aug 21, 2026Total Debt (MRQ)
969.50MCNY144.17M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3566xvs Biotechnology peers
Current Ratio (MRQ)
4.22xvs Biotechnology peers
Book Value per Share (MRQ)
6.74CNYUpdated Aug 21, 2026Total Assets
4.22BCNY627.85M · vs all stocks (USD)
Total Current Assets
2.06BCNYFY2025 · Dec 31, 2025Total Liabilities
1.56BCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.17BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
1.04BCNYFY2025 · Dec 31, 2025Total Current Liabilities
521.06MCNYFY2025 · Dec 31, 2025Cash
787.47MCNYFY2025 · Dec 31, 2025Cash Equivalents
4.90MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
792.37MCNYFY2025 · Dec 31, 2025Other Short-term Investments
161.52MCNYFY2025 · Dec 31, 2025Accounts Receivable
428.43MCNYFY2025 · Dec 31, 2025Inventory
644.88MCNYFY2025 · Dec 31, 2025Accounts Payable
338.85MCNYFY2025 · Dec 31, 2025Short-term Debt
43.26MCNYFY2025 · Dec 31, 2025Other Current Liabilities
31.11KCNYFY2025 · Dec 31, 2025Long-term Debt
933.08MCNYFY2025 · Dec 31, 2025Common Stock (Book)
406.20MCNYFY2025 · Dec 31, 2025Retained Earnings
1.43BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.66BCNY395.21M · vs all stocks (USD)
Treasury Stock
55.26MCNYFY2025 · Dec 31, 202552-Week Low
18.09CNYUpdated Aug 21, 202652-Week High
35.58CNYUpdated Aug 21, 202652-Week Change
-17.06%vs all stocks
Beta
-0.3570xvs all stocks
50-Day MA
19.84CNYUpdated Aug 21, 2026200-Day MA
23.71CNYUpdated Aug 21, 2026Avg 10-Day Volume
4.48MSharesUpdated Aug 21, 2026Avg 30-Day Volume
4.03MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
0.9600CNYUpdated Aug 21, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 5.17: safe zoneNotable
Altman Z-Score: 5.17
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.33B, above the global median of $1.15BNotable
Market cap (USD): 1,328,877,192.019Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Alphatec Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shandong Weigao Orthopaedic Device Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
SUDEEPPHRM
Tier 1ProductionApproval-Gated PipelineRuleFlow
North China Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Immatics N.V.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Changzhou Qianhong Biopharma Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Opm Biosciences Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Novavax Inc.
Tier 1ProductionApproval-Gated PipelineRule
EL.En. S.p.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Genpact Ltd.
2 interpretationsRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income Growth
Cyrela Brazil Realty S.A. Empreendimentos e Participações
2 interpretationsRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income Growth
CTS Eventim AG & Co. KGaA
2 interpretationsRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income Growth